Clinical Trials Completed For Human Bird Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
China's self-developed bird flu vaccine intended for humans has successfully completed Phase III clinical trials. China's State FDA has now approved the vaccine for production. Eight patients infected with highly pathogenic avian influenza H5N1 received treatment with the new vaccine in late December, and it It has been successful in three of them so far in China. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.